A Multicentric, Prospective Study Addressing the Kinetics and Impact on Survival of Measurable Residual Disease in Acute Myeloid Leukemia Patients Receiving Azacitidine and Venetoclax
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 225
- 主要终点
- Rate of MRD-negative patients within cycle 4
研究概览
简要总结
The goal of this no-profit, multicenter, biological, non-pharmacologic study is to evaluate minimal residual disease (MRD) in patients treated with Azacitidine and Venetoclax according to clinical practice.
The main questions it aims to answer are:
- kinetics of disease response on treatment with Azacitidine and Venetoclax through the evaluation of MRD with both cytofluorimetric and molecular techniques
- impact of MRD on survival outcomes. To this end, bone marrow samples will be collected at pre-defined time-points during treatment and MRD will be assessed.
详细描述
This is a multicentric biological study at evaluating MRD kinetics during treatment with Azacitidine and Venetoclax as well as the impact of MRD on survival outcomes.
Newly diagnosed, previously untreated, patients with AML, including de novo, secondary and therapy-related, receiving front-line therapy with Azacitidine and Venetoclax according to clinical practice will be included.
Response assessment will be performed on BM aspirate according to ELN2022 response criteria. MRD evaluation will be performed on BM at pre-defined time-points during treatment. MRD assessment will be performed centrally in order to harmonize response evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be ≥ 18 years of age
- •Subject has diagnosis of AML according to WHO 2016
- •Subject has newly diagnosed, previously untreated, AML, including de novo, secondary and therapy-related (cytoreduction with hydroxyurea is admitted prior treatment start)
- •Subject is planned to receive front-line therapy with Azacitidine and Venetoclax
- •Subject is ineligible for intensive induction chemotherapy according to investigator assessment according to clinical practice
- •Subject must have assessable MRD by flow cytometry at screening BM evaluation
- •Signed written informed consent according to ICH/EU/GCP and national local laws
排除标准
- •Diagnosis of BCR::ABL1-positive AML
- •Diagnosis of APL
- •AML with CNS involvement.
- •AML with extra-medullary localizations
- •Patients' unwillingness or inability to comply with the protocol requirements.
结局指标
主要结局
Rate of MRD-negative patients within cycle 4
时间窗: 4 months
Number of patients without minimal residual disease within cycle 4 on the total of subjects receiving at least one dose of study medication
次要结局
未报告次要终点